$PHIO
Phio Pharmaceuticals Corp Stock $phio

$phio Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000119312517336446 Filed on November 08, 2017

Income Statement

Concept	2017 Q4	2017 Q3	2016 Q4
Revenue	$20.00K	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$800.0K	$990.0K	$1.030M
YoY Change	-22.33%	32.0%	14.44%
% of Gross Profit
Research & Development	$1.200M	$1.490M	$1.310M
YoY Change	-8.4%	1.78%	-23.84%
% of Gross Profit
Depreciation & Amortization	$20.00K	$20.00K	$10.00K
YoY Change	100.0%	100.0%	-50.0%
% of Gross Profit
Operating Expenses	$2.010M	$2.476M	$2.340M
YoY Change	-14.1%	11.73%	-10.69%
Operating Profit		-$2.476M
YoY Change		11.73%
Interest Expense	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
% of Operating Profit
Other Income/Expense, Net	-$10.00K	$0.00	$0.00
YoY Change		-100.0%
Pretax Income	-$2.000M	-$2.480M	-$2.340M
YoY Change	-14.53%	12.22%	-10.69%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$2.000M	-$2.476M	-$2.340M
YoY Change	-14.53%	11.93%	-10.69%
Net Earnings / Revenue	-10000.0%
Basic Earnings Per Share
Diluted Earnings Per Share	-$50.00M	-$62.00M	-$234.0M
COMMON SHARES
Basic Shares Outstanding	23.70M shares	23.25M shares	6.600M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q4	2017 Q3	2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.580M	$5.420M	$12.91M
YoY Change	-72.27%	23.74%	21.56%
Cash & Equivalents	$3.581M	$5.416M	$12.91M
Short-Term Investments
Other Short-Term Assets	$250.0K	$320.0K	$200.0K
YoY Change	25.0%	-13.51%	-44.44%
Inventory
Prepaid Expenses		$271.0K	$150.0K
Receivables
Other Receivables
Total Short-Term Assets	$3.832M	$5.737M	$13.11M
YoY Change	-70.76%	20.78%	19.38%
LONG-TERM ASSETS
Property, Plant & Equipment	$248.0K	$269.0K	$114.0K
YoY Change	117.54%	116.94%	-30.06%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$18.00K	$27.00K	$27.00K
YoY Change	-33.33%	0.0%	50.0%
Total Long-Term Assets	$266.0K	$296.0K	$291.0K
YoY Change	-8.59%	96.03%	60.77%
TOTAL ASSETS
Total Short-Term Assets	$3.832M	$5.737M	$13.11M
Total Long-Term Assets	$266.0K	$296.0K	$291.0K
Total Assets	$4.098M	$6.033M	$13.40M
YoY Change	-69.41%	23.1%	20.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$511.0K	$702.0K	$917.0K
YoY Change	-44.27%	53.61%	-21.15%
Accrued Expenses	$1.754M	$1.901M	$1.625M
YoY Change	7.94%	35.01%	46.93%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.265M	$2.603M	$2.542M
YoY Change	-10.9%	39.57%	12.03%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.265M	$2.603M	$2.542M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$2.270M	$2.600M	$2.540M
YoY Change	-10.63%	39.04%	11.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$78.55M	-$76.55M	-$66.10M
YoY Change	18.84%	20.06%	15.75%
Common Stock	$0.00	$2.000K	$0.00
YoY Change		100.0%	-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.833M	$3.430M	$10.86M
YoY Change
Total Liabilities & Shareholders Equity	$4.098M	$6.033M	$13.40M
YoY Change	-69.41%	23.1%	20.06%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2016 Q4
OPERATING ACTIVITIES
Net Income	-$2.000M	-$2.476M	-$2.340M
YoY Change	-14.53%	11.93%	-10.69%
Depreciation, Depletion And Amortization	$20.00K	$20.00K	$10.00K
YoY Change	100.0%	100.0%	-50.0%
Cash From Operating Activities	-$2.200M	-$2.190M	-$1.370M
YoY Change	60.58%	36.88%	-13.29%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$10.00K	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$1.850M
YoY Change	-100.0%		-26.0%
Cash From Investing Activities	$0.00	-$10.00K	$1.850M
YoY Change	-100.0%		-25.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$10.05M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	360.0K	-70.00K	10.05M
YoY Change	-96.42%	-146.67%	5189.47%
NET CHANGE
Cash From Operating Activities	-2.200M	-2.190M	-1.370M
Cash From Investing Activities	0.000	-10.00K	1.850M
Cash From Financing Activities	360.0K	-70.00K	10.05M
Net Change In Cash	-1.840M	-2.270M	10.53M
YoY Change	-117.47%	56.55%	866.06%
FREE CASH FLOW
Cash From Operating Activities	-$2.200M	-$2.190M	-$1.370M
Capital Expenditures	$0.00	-$10.00K	$0.00
Free Cash Flow	-$2.200M	-$2.180M	-$1.370M
YoY Change	60.58%	36.25%	-12.18%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q3	us-gaap	Assets Assets	6033000
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5416000
CY2017Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2017Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1901000
CY2017Q3	us-gaap	Assets Current AssetsCurrent	5737000
CY2017Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	79977000
CY2017Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	702000
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	23697338	shares
CY2016Q3	rxii	Cash And Cash Equivalents And Restricted Cash At Carrying Value CashAndCashEquivalentsAndRestrictedCashAtCarryingValue	2429000
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23697338	shares
CY2017Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	14077779	shares
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23697338	shares
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	2000
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6033000
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2603000
CY2017Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	27000
CY2017Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q3	us-gaap	Preferred Stock Value PreferredStockValue
CY2017Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	271000
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	269000
CY2017Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	50000
CY2017Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	50000
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-76549000
CY2017Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	354959	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	18.20
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	3430000
CY2017Q3	rxii	Cash And Cash Equivalents And Restricted Cash At Carrying Value CashAndCashEquivalentsAndRestrictedCashAtCarryingValue	5466000
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	26.21
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	531006	shares
CY2015Q4	rxii	Cash And Cash Equivalents And Restricted Cash At Carrying Value CashAndCashEquivalentsAndRestrictedCashAtCarryingValue	5167000
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1625000
CY2016Q4	us-gaap	Assets Current AssetsCurrent	13106000
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	73428000
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	917000
CY2016Q4	us-gaap	Assets Assets	13397000
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12906000
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13003179	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13003179	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13397000
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2542000
CY2016Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	150000
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	27000
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2016Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	150000
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	114000
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	50000
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	50000
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-66099000
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	374446	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	27.29
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	10855000
CY2016Q4	rxii	Cash And Cash Equivalents And Restricted Cash At Carrying Value CashAndCashEquivalentsAndRestrictedCashAtCarryingValue	12956000
CY2017Q1	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	2750371	shares
CY2017Q1	rxii	Holdback Percentage HoldbackPercentage	0.03	pure
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14608785	shares
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	100000
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	48000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.47
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	dei	Entity Registrant Name EntityRegistrantName	RXi Pharmaceuticals Corp
	dei	Entity Central Index Key EntityCentralIndexKey	0001533040
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	2824000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3209000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	276000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-417000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	121000
	us-gaap	Maturities Of Time Deposits Description MaturitiesOfTimeDepositsDescription	Three months or less
	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>1. Nature of Operations</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> RXi Pharmaceuticals Corporation (“<b>RXi</b>,” “<b>we</b>,” “<b>our</b>” or the “<b>Company</b>”) is a clinical-stage company developing innovative therapeutics based on our proprietary self-delivering RNAi <font style="white-space:nowrap">(sd-rxRNA</font><sup style="font-size:85%; vertical-align:top">®</sup>) platform and Samcyprone™ which address significant unmet medical needs. We have a pipeline of discovery, preclinical and clinical product candidates in the areas of dermatology, ophthalmology and cell-based cancer immunotherapy. The Company’s clinical development programs include <font style="white-space:nowrap">RXI-109,</font> an <font style="white-space:nowrap">sd-rxRNA</font> for the treatment of dermal and ocular scarring, and Samcyprone™, a topical immunomodulator, for the treatment of warts. The Company’s pipeline, coupled with our extensive patent portfolio, provides for product development and business development opportunities across a broad spectrum of therapeutic areas.</p> </div>
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-103000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-7313000
	us-gaap	Operating Expenses OperatingExpenses	10450000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-74000
	us-gaap	Net Income Loss NetIncomeLoss	-10450000
	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	5000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10450000
	us-gaap	Notes Reduction NotesReduction	150000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	203000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	-74000
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	3075000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4166000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.8299	pure
	us-gaap	Share Based Compensation ShareBasedCompensation	276000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.2301	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0173	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.49
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.69
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	173824	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	4.48
	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.8465	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	22000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0249	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	330384	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	2750371	shares
	dei	Trading Symbol TradingSymbol	RXII
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22167753	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <i>Uses of Estimates in Preparation of Financial Statements</i></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</p> </div>
	rxii	Cash And Cash Equivalents And Restricted Cash Period Increase Decrease CashAndCashEquivalentsAndRestrictedCashPeriodIncreaseDecrease	-7490000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1691433	shares
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	41000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.02
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2587000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	302000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-706000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	10000
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	15000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	3498000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6388000
	us-gaap	Operating Expenses OperatingExpenses	6695000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	152000
	us-gaap	Net Income Loss NetIncomeLoss	-6655000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6676000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	21000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2000
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	2000000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	152000
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	5500000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4108000
	us-gaap	Revenues Revenues	19000
	us-gaap	Share Based Compensation ShareBasedCompensation	649000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.1688	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7942	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0118	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.15
	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.8912	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0202	pure
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6548696	shares
	rxii	Value Of Nonmarketable Equity Securities Recognized As Revenue ValueOfNonmarketableEquitySecuritiesRecognizedAsRevenue	9000
	rxii	Cash And Cash Equivalents And Restricted Cash Period Increase Decrease CashAndCashEquivalentsAndRestrictedCashPeriodIncreaseDecrease	-2738000
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	752000
CY2016Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	4000
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	2216000
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-2212000
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2216000
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4000
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1464000
CY2016Q3	us-gaap	Share Based Compensation ShareBasedCompensation	128000
CY2016Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0146	pure
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.27
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.1688	pure
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	1.1688	pure
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6576096	shares
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	986000
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	2476000
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-2476000
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2476000
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1490000
CY2017Q3	us-gaap	Share Based Compensation ShareBasedCompensation	43000
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.9199	pure
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.8387	pure
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0194	pure
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.49
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.8793	pure
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0235	pure
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23511444	shares

Files In Submission

Name	View Source	Status
0001193125-17-336446-index-headers.html	Edgar Link	pending
0001193125-17-336446-index.html	Edgar Link	pending
0001193125-17-336446.txt	Edgar Link	pending
0001193125-17-336446-xbrl.zip	Edgar Link	pending
d463715d10q.htm	Edgar Link	pending
d463715dex31.htm	Edgar Link	pending
d463715dex311.htm	Edgar Link	pending
d463715dex32.htm	Edgar Link	pending
d463715dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rxii-20170930.xml	Edgar Link	completed
rxii-20170930.xsd	Edgar Link	pending
rxii-20170930_cal.xml	Edgar Link	unprocessable
rxii-20170930_def.xml	Edgar Link	unprocessable
rxii-20170930_lab.xml	Edgar Link	unprocessable
rxii-20170930_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PHIO
Phio Pharmaceuticals Corp Stock $phio

2017 Q4 Form 10-Q Financial Statement

#000119312517336446 Filed on November 08, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PHIO Phio Pharmaceuticals Corp Stock $phio

2017 Q4 Form 10-Q Financial Statement

#000119312517336446 Filed on November 08, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PHIO
Phio Pharmaceuticals Corp Stock $phio